FAQ

fowlpox-NY-ESO-1 vaccine

Known as: rF-NY-ESO-1 
A cancer vaccine consisting of a recombinant fowlpox virus vector encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1, an… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2014
02420002014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.
During cancer progression, malignant cells may evade immunosurveillance. However, evidence for immunological escape in humans is… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.
Recombinant poxviruses (vaccinia and fowlpox) expressing tumor-associated antigens are currently being evaluated in clinical… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
NY-ESO-1 is a prototypic cancer/testis antigen. In a recent phase I clinical trial, we vaccinated 13 patients bearing NY-ESO-1… (More)
Is this relevant?
2008
2008
Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells
NY-ESO-1, one of the most immunogenic cancer/testis antigens, provides attractive targets for cancer immunotherapy. NY-ESO-1 has… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.
NY-ESO-1 is a cancer/testis antigen expressed in a range of human malignancies, and a number of vaccine strategies targeting NY… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2005
2005
Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma.
Immunotherapy is being proposed to treat patients with hepatocellular carcinoma (HCC). However, more detailed knowledge on tumor… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2004
2004
NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.
NY-ESO-1 is a cancer/testis antigen expressed in normal adult tissues solely in the testicular germ cells of normal adults and in… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
Is this relevant?
2004
2004
Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
PURPOSE For the development of peptide-based, cancer-specific immunotherapy, the identification of CTL epitopes from additional… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 5
Is this relevant?
2002
2002
Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
NY-ESO-1 is one of the most immunogenic cancer antigens known to date, inducing humoral and cellular immune responses in a high… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.
NY-ESO-1, a member of the cancer-testis family of antigens, is expressed in a subset of a broad range of different human tumor… (More)
Is this relevant?